The Company's Scientific Advisory Board is compromised of scientists and doctors who are experienced with the various technologies to be utilized by the Company. The Scientific Advisory Board advises the Company's management on various projects and matters including product development, clinical trials and physician training programs.

Please read the complete listing below to find out more detailed information about the Scientific Advisory Board and the board members who currently hold positions on it.

Bioheart, Inc. Headquarters: 4th Floor 1/4
Tour Our Facilities

Management Page

Bioheart, Inc. Site Menu
Bioheart Genotyping, Inc.
Bioheart Health Plans
What's New
Bioheart MicroImplants
Stem Cell Labs, Inc.
Main Site Index Page
Scientific Advisory Board Bioheart, Inc.


Each Scientific Advisory Board member has entered into a three-year agreement to provide services to the Company as a member of the Scientific Advisory Board. The Scientific Advisory Board members are not compensated in cash for their services on the Scientific Advisory Board except for expense reimbursements. Each member of the Scientific Advisory Board has been granted options to purchase Common Stock in consideration for their services on the Scientific Advisory Board and/or in other capacities, such as their services under their respective consulting or other agreements with the Company, as the case may be (see "1999 Directors and Consultants Stock Option Plan" below). Members of the Scientific Advisory Board may resign without notice at any time.

The Scientific Advisory Board [currently] consists of the following individuals:

Daniel Burkhoff, M.D., Ph.D., is an Associate Professor of Medicine and Director of Cardiac Physiology Laboratory at Columbia University, New York, New York.

Ray Chiu, M.D., Ph.D., is a Professor of Surgery at McGill University and is also a Consultant to Bioheart. See "Other Key Employees and Consultants" above for additional information about Dr. Chiu.

Edward Diethrich, M.D., is [the Director of the Arizona Heart Hospital in Phoenix, Arizona, and a cardiovascular surgeon].

Pascal Goldschmidt, M.D., FACC Chief Consultant for Genetic Testing. Dr. Goldschmidt [has entered] into a three-year consulting agreement with the Company to provide consulting services as Chief Consultant for Genetic Testing for the Company, including advice to the Company with respect to genetic testing and related technologies and matters. A native of Belgium, Dr. Goldschmidt earned his undergraduate degree in biochemistry and graduated magna cum laude in 1976 and earned his medical degree in 1980 and graduated summa cum laude from the Universite Libre de Bruxelles in Brussels, Belgium. Following a medicine and cardiology residency at the Erasme Academic Hospital in Belgium and a fellowship in molecular biology and immunology at the Medical University of South Carolina, Dr. Goldschmidt completed a five year residency training in cardiology and cell biology at Johns Hopkins University. In 1991, he joined the cardiology faculty of Johns Hopkins University where he was the Director of the Bernard Vascular Biology Laboratory, Co-Director of the Thrombosis Center and Co-Director of the Henry Ciccarone Center for the Prevention of Heart Disease. In 1996 he received a faculty appointment in the Department of Pathology at the Johns Hopkins University. In 1997, Dr. Goldschmidt joined The Ohio State University as a Professor of Medicine and was named the John H. and Mildred C. Lumley Chair in Medicine and the Director of the new Heart and Lung Institute after a search process that reviewed 175 leaders in the field. In 1998, Dr. Goldschmidt was named the Director of the Division of Cardiology at The Ohio State University. A landmark in Dr. Goldschmidt's career was his discovery of the first inherited thrombogenic risk factor for coronary heart disease. Dr. Goldschmidt is internationally recognized for his research in the molecular mechanisms of cardiovascular disease. He has received numerous honors, including the Established Investigator Award from the American Heart Association and is a Fellow of the American College of Cardiology. As a result of his reputation within the medical community, Dr. Goldschmidt has been selected as an expert clinician and scientist for many organizations and is a reviewer for several top medical journals including the New England Journal of Medicine, the Annals of Internal Medicine, and Circulation. He has authored or co-authored over 80 articles in all top peer-reviewed journals including Science, Cell, the New England Journal of Medicine, the Lancet and the Journal of Clinical Investigation. Dr. Goldschmidt has also been awarded several grants from the NIH, Scleroderma Research Foundation and the American Heart Association for his research in cardiovascular disease and molecular genetics. Dr. Goldschmidt is a member of and serves on many committees for the American Association for the Advancement of Science, the American Heart Association, the American Society of Clinical Investigation, the American College of Cardiology, and the American Medical Association.

Barry Katzen, M.D., is currently [the Director of the Miami Cardiac and Vascular Institute, in Miami, Florida] and Clinical Professor of Radiology at the University of Miami School of Medicine. A 1970 graduate of the University of Miami School of Medicine, Dr. Katzen completed diagnostic radiology training at the New York Hospital-Cornell University Medical Center in New York. He then trained in Vascular and Interventional Radiology at the University of Rome under Dr. Plinio Rossi. Dr. Katzen is a member of the North American Chapter of the International Society for Cardiovascular Surgery and has been elected to fellowship in the American College of Cardiology, the American College of Radiology and the Society of Cardiovascular and Interventional Radiology, of which he is the past president. Dr. Katzen has been a leader in the development of interventional radiology, and more recently in the development of multi-disciplinary models for delivering cardiovascular care. He has contributed extensively to the scientific literature and is a member of the Editorial Board of The Journal of Vascular and Interventional Radiology, and is a manuscript reviewer for numerous scientific journals. He has lectured extensively, both abroad and within the United States, on topics including thrombolysis, multi-disciplinary models of practice, and innovative endovascular techniques.

Zvonimir Krajcer, M.D., is [the Director of Texas Heart Institute. Dr. Krajcer graduated from University of Zagreb in Croatia. Dr. Krajcer attended Northwestern University and is certified by the American Board of Internal Medicine in cardiovascular disease. Dr. Krajcer's specialty interests include clinical cardiology, cardiac catheterization, interventional cardiology, pacemakers, atherectomy, laser angioplasty, cardiac transplantation, stent-grafts for treatment of thoracic and abdominal aortic aneurysms, carotid artery stenting, and treatment of peripheral vascular disease.

Stephen Ramee, M.D., is Director of Cardiology and the Cath Lab at Oschner Clinic.

Syde A. Taheri, M.D., is a Cardiovascular and Thoracic Surgeon at Millard Fillmore Hospital, Buffalo, New York, and is also a Consultant to Bioheart. See "Other Key Employees and Consultants" above for additional information about Dr. Taheri.

Doris Taylor, Ph.D., is an Assistant Research Professor in the Departments of Medicine and Surgery at Duke University Medical Center and is also a Director of, and a Consultant to, Bioheart. See "Executive Officers and Directors" above for additional information about Dr. Taylor.

Stuart Williams, Ph.D., Chief Consultant for Tissue Engineering. Professor of Biomedical Engineering, Surgery, Physiology, and Material Science Engineering, University of Arizona Health Sciences Center. Ph.D. Cell Biology-Physiology, U of Deleware, Post-Doc. Yale University School of Medicine. Dr. Williams is one the premier scientists in the world regarding tissue engineering. He is President of the International Society for Applied Cardiovascular Biology. He has published over 100 papers in his career related to cardiovascular biology.

Other new members include; Sam Ahn, M.D. Professor of Surgery at U.C.L.A., Peter Law, M.D. of The Cell Therapy Research Foundation in Memphis, TN, and Michael Franz, M.D. an electrophysiologist specializing in monphasic action potential monitoring from Washington D.C.




Bioheart, Inc. | |
Telephone: | Fax: | email: